About this trial
Covid-long pathology affects a large number of patients, and represents a major medical, economic and societal challenge. To date, we have no objective criterion for a definitive diagnosis, nor any predictive tool for monitoring the evolution of Covid-long. Based on recruitment from the infectious diseases department of Nice University Hospital, the investigator's team wants to conduct an innovative pathophysiological study to better define the disease and identify specific biomarkers that could subsequently be used as a diagnostic tool for Covid-long. 120 participants will be initially included for the model learning phase: 60 controls in the CL- cohort and 60 patients in the CL+ cohort. Then 80 patients (40 CL+ and 40 Cl-) will be enrolled for the model validation phase.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Case definition in line with WHO Delphi process
Disqualifiers
History of chronic fatigue syndrome diagnosed before or after Covid.
History of progressive psychiatric pathology.
History of acute Covid requiring admission to intensive care and mechanical ventilation.
No social security affiliation.
Trial design
Parallel
Treatments tested in this trial
Brain MRI
Procedure/Surgerynon injected brain MRI
Specific blood samples
Biological/Vaccineblood samples to find immunological and inflammatory markers
Treatment groups
Trial outcomes
Primary outcomes
Predictive model of Covid-long
Build and validate a multivariate predictive model of Covid-long considering immunological, inflammatory and brain imaging markers.
Secondary outcomes
Evolution of these markers over time
Comparison of data over time between cohorts (CL+ vs. CL-)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.